Women’s Health Breakfast to Focus on Female Heart Issues

Claire Holt's picture
No votes yet

After the success of the inaugural event in 2012, which focused on 3D mammography, this year’s Women’s Health Breakfast will concentrate on female heart health.  The aim of the event is to allow attendees to hear about, and discuss, the advances in care and research projects at the University of Connecticut (UConn) health center.  In recognition of the fact that heart disease is the biggest killer of women in The United States, this year the topics will be the consideration of a genetic link between heart disease and infertility and managing cholesterol levels and preventing female heart disease.

The Breakfast in Detail

This year’s venue for the Women’s Health Breakfast is the Pond House Cafe in West Hartford.  The event will run from 8:00am to 9:30am on Thursday October 17 2013, with a fee to attend of either $25, making a donation of $12.50 towards the new Cardio-Metabolic Clinic at the Pat and Jim Calhoun Cardiology Center, or $100, making an $88.50 donation.  Bruce T. Liang, M.D., F.A.C.C. will host the breakfast; Dr. Liang is a graduate of Harvard Medical School and a fellow of the American Heart Association and the American College of Cardiology.  Currently he is Director at the Pat and Jim Calhoun Cardiology Center.  Speaking at the event will be Dr. Annabelle Rodriguez-Oquendo.

The Study of Heart Disease and Infertility Links

Dr. Rodriguez-Oquendo, associate professor in cell biology, will be speaking about her research into the possible link between healthy HDL cholesterol, infertility, and heart disease in females.  She has secured a grant to continue her work at the UConn health center; a study which she brought with her from her previous post at Johns Hopkins University School of Medicine.  The research involves looking into what role is played by a genetic mutation which causes women with high levels of healthy HDL to encounter heart disease and infertility.  There have so far been some encouraging results when the effects of the SCARB1 gene mutation have been reversed by using medication to reduce cholesterol.  Events such as the breakfast prove valuable to professionals like Dr. Rodriguez-Oquendo who believes that it is vitally important to communicate the value of her work to the public as a whole.  She wants people to see beyond the technical terms and realize that she is attempting to assist women with fertility and coronary health issues.

Developments in Coronary Health Care

For those suffering from heart disease understanding the information about, and treatments for, the condition is extremely important.  The Centers for Disease Control and Prevention (CDC) provide clear and relevant advice on the intricacies of heart disease from signs and symptoms to statistical information, and methods of possible prevention.  In the treatment arena advancements are often reported.  The US Food and Drug Administration (FDA) has just authorized revised labeling for the revolutionary Sapien Transcatheter Heart Valve (THV) which means that the device is now available for use in a wider group of patients with inoperable aortic valve stenosis.  According to licensedprescriptions.com the THV is “…a viable alternative to having complicated and often dangerous open heart surgery… it can be inserted through a small incision in the ribcage rather than having to open the chest cavity to operate, it promises a simpler operation with a quicker recovery time.” The product labeling change was supported by evidence from European use of the THV, medical journals, and clinical testing which was FDA approved.  Evidence was also compiled from the Transcatheter Valve Therapy Registry (TVTR).  This is a valuable tool, launched in 2012, which allows clinical data in relation to transcatheter aortic valve replacements to be stored.  From this data information can be gleaned about the short and long term outlook for patients.  According to Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health; “Medical device registries like the TVTR, not only play an important role in the FDA’s post market surveillance system, they also collect robust and timely data that can be used to identify additional patient populations that benefit from the therapy. “

Prevention as well as Treatment

Data collection is not just important in the treatment of heart disease but is also vital for experts such as Dr. Annabelle Rodriguez-Oquendo in her fight to help prevent heart disease in women.  Dr. Rodriguez-Oquendo will use this data to help inform her speech at the Women’s Health Breakfast, and to take her work forward.  We look forward to the results with interest.

Blog Category: 

Add new comment